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Alzheimer’s disease is a neurodegenerative disorder characterised by the 
accumulation, in the brain, of neurotoxic amyloid beta-(Aβ) peptides. These peptides 
are generated from the amyloid precursor protein (APP) via the amyloidogenic 
proteolytic pathway which also leads to the formation of soluble APP beta (sAPPβ). 
Alternatively, APP can be cleaved by the non-amyloidogenic pathway in which an α-
secretase activity cleaves the protein within the Aβ region generating soluble APP 
alpha (sAPPα). APP itself binds to copper at a number of sites, including a recently 
identified E2 copper binding domain (E2 CuBD) within the extracellular region of the 
protein. The current project aims were to investigate how copper binding within the 
APP E2 CuBD might influence the expression, proteolysis, cellular localisation and 
cytotoxicity of APP. In order to achieve this, a range of E2 CuBD mutants were 
generated in which various metal-co-ordinating histidine residues were mutated to 
alanine. These constructs were expressed in HEK and SH-SY5Y cells and the effects 
of the mutations on the afore mentioned properties of APP were assessed. The results 
show that these mutations had little consistent effect on the expression, proteolysis or 
cellular localisation of APP. Furthermore, whilst wild-type APP accentuated copper-
mediated cytotoxicity in HEK and SH-SY5Y cells, mutating the histidine residues in 
the E2 domain of the protein had little effect on this phenomenon. Thus, it would 
appear that copper binding to the E2 domain of APP is, most likely, not an important 
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ADAM A disintegrin and metalloproteinase 
AICD APP intracellular domain  
APP Amyloid precursor protein 
APP-E1 CuBD Amyloid precursor protein E1 copper binding domain 
APP-E2 CuBD Amyloid precursor protein E2 copper binding domain 
Aβ Amyloid beta  
BACE1 Beta-site APP-cleaving enzyme 1  
BCA Bicinchoninic acid assay 
BSA Bovine Serum Albumin 
CNS Central nervous system   
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CTF-83 C-terminal fragment of 83 amino acids  
CTF-99 C-terminal fragment of 99 amino acids  
CTR1 Copper plasma membrane transporter 1 
DAPI 4', 6-diamidino-2-phenylindole  
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GFD Growth factor domain 
GWAS Genome-Wide Association Studies  
HBD Heparin binding domain  
HEK Human embryonic kidney  
KPI Kunitz-type protease inhibitor  
LB Liquid broth 
LRP1 low density lipoprotein receptor-related protein 1  
NCT  Nicastrin  
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PSEN1 Presenilin 1  
PSEN2 Presenilin 2 
sAPPα soluble APP alpha 
sAPPβ soluble APP beta 
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 Dementia is a generic term for diseases which involve neuronal death or 
malfunctioning, resulting in decreased cognitive and functional abilities (manifested 
as detrimental  alterations in behaviour, language and memory) [5]. Alzheimer’s 
disease (AD) is a progressive neurodegenerative condition that is estimated to be 
responsible for 60-80% of all dementia cases worldwide. In 2006, the prevalence of 
AD was 26.5 million worldwide; in an ageing population this number is set to increase 
dramatically with projections estimated at 106 million by 2050 [6]. The cost of AD to 
the UK economy is an estimated £23 billion per year with each dementia patient 
costing the economy £28,000 per annum. 
 
1.1.1. History 
 In 1907, Alois Alzheimer used silver staining to demonstrate the presence of 
neurofibrillary tangles (NFTs) (later shown to consist of aggregated tau protein) and 
senile plaques within the post-mortem brain of a 55 year old woman who had suffered 
from memory loss, delusions and a decline in cognitive ability [7]; his co-worker, 
Emile Kraeplin, subsequently named the condition Alzheimer’s disease. It was 
initially thought that plaques and tangles were specific to AD but this was disputed 
when senile plaques and NFTs were identified in 84% and 97% of ageing brains 
respectively, (reviewed in [8]), suggesting that they were a common feature of ageing. 
These pathological hallmarks were only definitively associated with dementia in 1968 
when Blessed et al. [8] demonstrated a strong correlation between plaque burden and 
dementia scores.  
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1.1.2. Pathological hallmarks of the disease 
 Two key pathological hallmarks are associated with the AD-afflicted brain; 
neurofibrillary tangles and senile plaques (Fig. 1.1). NFTs are formed intracellularly 
when the hyperphosphorylated form of the microtubule-associated protein, tau, mis-
folds and relocates to the neuronal soma from the neuronal microtubules. The 
damaged dendrites of neurons that have died as a result of tangle formation degrade to 
form neopril threads (Fig 1.1) [9].  The loss of normal tau functioning and neuronal 
degeneration are thought to inhibit normal axonal transport and contribute to cerebral 








Figure 3.1. Microscopic pathology of the AD-afflicted brain showing large dense-core senile 
plaques and neurofibrillary tangles. Adapted from Bird [11]. 
  
The extracellular dense-core senile plaques in the AD-afflicted brain comprise 
mainly of amyloid beta (Aβ)-peptides. These peptides aggregate first to form early 
oligomers before assembling into the mature plaques [9]. Whether it is the mature 
plaques or the early oligomers that form the neurotoxic entities in AD is the subject of 
some debate [12, 13] 
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 Many studies have shown that both Aβ-peptides and NFTs are neurotoxic and 
that their regional distribution within the brain correlates with the symptoms 
manifested in AD (reviewed in [9]). However their role in disease pathogenesis has 
also been questioned as a result of their presence in the normal aged brain (reviewed 
in [14] and [15]). 
 
1.1.3. Symptoms 
 AD is often preceded by the onset of mild cognitive impairment (MCI) which 
is defined as a decline of cognitive function greater than expected for an individual's 
age and educational background [16]. It has been shown that 22% of individuals 
diagnosed with MCI progressed to some form of dementia over a three year period 
[17], although specific studies on AD have demonstrated a range of progression rates 
from 11-33% over two years and that a diagnosis of MCI does not necessarily mean a 
certain progression to AD [16]. The progression of symptoms from MCI to severe 
dementia is described in the global deterioration scale (GDS) by Reisberg et al.  [18]. 
MCI is described as a loss of memory noticeable to family and friends, where the 
individual may lose important items or struggle to retain information. As MCI 
progresses to moderate dementia, the individual often struggles to recall the date and 
previous memories, cope with day-to-day life and dress appropriately. Ultimately the 
dementia progresses to the severe criteria for which symptoms include; major 
behavioural disruptions, an inability to recognise loved ones and incontinence, with a 
complete loss of psychomotor skills and speech [18]. 
1.1.4. Diagnosis 
 In the UK, a diagnosis of AD begins with the exclusion of other possible 
conditions. Clinical cognitive assessments are used to measure cognition, function and 
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behaviour. Most frequently, a lower than average score in the Mini Mental State 
Examination (MMSE) is used to diagnose dementia. Following this, structural 
imaging such as magnetic resonance imaging or computed tomography would then be 
used in order to determine the specific subtype of dementia [19]; AD is generally 
defined by atrophy in the temporal lobes and hippocampus.  
 
1.1.5. Treatment 
 Current therapies approved by the UK drugs regulatory agency target the 
neurotransmitter dysfunction observed in AD. Cholinesterase inhibitors, prescribed 
during early- to mid-AD, reduce the degradation of acetylcholine in the synaptic cleft. 
The three cholinesterase inhibitors currently recommended by the National Institute 
for Health and Care Excellence (NICE) for the treatment of cognitive symptoms 
include donepezil, galantamine and rivastigmine [19]. However, a meta-analysis of 
these treatments demonstrated only a modest improvement in function, cognition and 
behaviour compared with placebo (summarised in Table 1.1) [20].  
 Memantine is a non-competitive N-methyl-D-aspartate (NMDA) receptor 
antagonist postulated to protect neurons against toxicity mediated by excess 
glutamatergic activity. Benefits of memantine include improvements in long term 
potentiation and decreased tau hyperphosphorylation (reviewed in [21] ). Like the 
acetylcholinesterase inhibitors, the effects of memantine on cognition are modest and 
only significant during the later stages of AD [21]. Neither therapeutic approach cures 




 Test Test scale Average weighted 







70 point scale with higher scores 





144 point scale with higher scores 





Multiple measures of 
function used 
Mean changes and standard 
deviations of individual tests 
combined. Increased values 




Table 1.1. Results of a meta-analysis examining the effects of cholinesterase inhibitors on 
cognition versus placebo. Adapted from Hanson et al. [20]. 
 
1.1.6. Prognosis 
 As a result of late diagnosis and a lack of effective treatments, the prognosis of 
AD is poor. Median survival after diagnosis has been estimated at 4.2 years in men 
and 5.7 years in women. The MMSE score at diagnosis is an effective marker of 
survival [22]. As neurodegeneration starts to affect the pre-and postcentral gyri, 
frontal operculum and Rolandic operculum of the brain, the patient loses the ability to 
swallow [23]. Malnutrition, infection and aspiration pneumonia are common causes of 
death in patients, as are urinary tract infections caused by the degeneration of regions 
of the brain responsible for bladder control. The relative risks of pneumonia/bronchitis 
and infectious disease in individuals with  AD are 2.26 and 1.51 compared with age-




1.2. Etiology and genetics of Alzheimer's disease 
1.2.1. Etiology 
 The definitive cause of progressive neural damage observed during AD has yet 
to be determined although there are four key hypotheses in this respect; the vascular 
theory, the tau theory, the oxidative stress theory and the amyloid cascade theory.  
The vascular theory  
The vascular theory of AD proposes that altered cerebrovascular systems in 
the body caused by both age and vascular disorders are the major cause of AD. The 
altered systems create vascular uncoupling and cerebral hypoperfusion which in turn 
stimulate abnormal angiogenesis, endothelial death and oxidative stress in the vascular 
systems of the brain. Ultimately, the compromised blood brain barrier (BBB) and 
reduced cerebral blood flow lead to synaptic injury and neuronal atrophy, which 
induce MCI and dementia [25]. The compromised BBB may further lead to 
ineffective clearance of Aβ due to changes in transport proteins such as low density 
lipoprotein receptor related protein-1 (LRP1) [26].  Several lines of evidence support 
this theory as the major etiological cause of AD. Individuals with atherosclerosis, 
which reduces cerebral blood flow,  are at increased risk of AD which is potentiated 
by the severity of the atherosclerosis [27]. In addition, mutant murine models of 
diminished Aβ clearance across the BBB, which occurs when the BBB is 
compromised, exhibit increased plaque number and deposition  increased 
neurotoxicity [28].  
The tau theory 
The tau theory proposes that the hyperphosphorylation of the microtubule-
associated tau protein induces the neurotoxicity and degeneration in AD. Studies have 
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demonstrated that tau hyperphosphorylation can be caused by increasing Aβ levels, 
dysregulation of phosphorylation or abnormal glucose metabolism (reviewed in [29]). 
The hyperphosphorylated tau loses its normal biological activity, and polymerises to 
form NFTs. Soluble hyperphosphorylated tau has also been shown to be neurotoxic 
causing neuronal atrophy, impaired axonal transport and compromised microtubule 
networks  [29]. Recent  research suggests that tau abnormalities occur downstream of 
Aβ accumulation and that increasing cerebral Aβ levels may initiate the formation of 
NFTs [10].  
A core finding in support of the tau theory of AD is that NFT distribution 
within the brain mirrors AD neuropathology more closely than Aβ plaques [9]. 
Further support has been shown by Roberson et al. [30] who demonstrated that mice 
overexpressing APP (APP+/+) exhibited significant difficulties in spatial learning and 
memory compared to WT mice. The authors also showed that knocking out 
endogenous tau in APP +/+ mice returned spatial learning and memory scores to those 
observed in wild-type mice. Knocking out tau did not affect Aβ levels, suggesting that 
tau, rather than Aβ may be the cause of neurodegeneration in AD. More recently, it 
has been shown that sequestration of zinc by Aβ plaques reduces intra-neuronal zinc 
available to tau which subsequently destabilises microtubules [31]. This also provides 
a potential link between Aβ and tau neurotoxicity.  
The oxidative stress theory of AD 
Oxidative stress was initially proposed as a cause of AD due to its involvement 
in the pathophysiology of other diseases including Parkinson’s, Down’s syndrome and 
amyotrophic lateral sclerosis [32]. It is proposed that reactive oxygen species (ROS) 
generated from a number of processes including ageing and the reduction of metals in 
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amyloid plaques cause peroxidation of cell membrane polyunsaturated fatty acids. 
ROS can be generated both outside the cell through environmental factors, and inside 
the cell via membrane bound, mitochondrial or cytosolic factors. In the presence of 
redox metals, hydrogen peroxide also undergoes Fenton’s chemistry to produce 
hydroxyl radicals [33]. ROS damage the cell membrane and mitochondria, and disturb  
Na/K ATPase’s which increase intracellular calcium leading to cell death and further 
free radical generation [32].  This irreversible damage to cells is postulated to cause 
the neuronal atrophy observed in AD. 
Epidemiological studies have revealed that markers of lipid peroxidation are 
significantly higher in AD brains than age-matched controls and oxidative stress 
markers are perturbed early in the disease (reviewed in [34]) which support a role of 
oxidative stress in the pathogenesis of AD. In vitro studies have found increased 
peroxidation markers in cells exposed to copper which correlates with cell toxicity 
[35]. Furthermore, a randomised controlled trial of 341 patients found that those who 
received the antioxidant vitamin E exhibited significant delays in the time until 
institutionalisation, death or severe dementia relative to placebo [36]. This supports an 
in vivo role of oxidative stress in the pathogenesis of AD. 
The amyloid cascade theory 
The amyloid cascade hypothesis is the most well acknowledged etiological 
theory of AD. This is due to early studies identifying that all early-onset familial AD 
(EOFAD) mutations disrupt normal APP processing (reviewed in [37]). It proposes 
that altered processing of APP or decreased Aβ clearance results in increased Aβ 
aggregation in the extracellular space of the brain. The updated hypothesis proposes 
that soluble Aβ oligomers, over Aβ plaques, induce toxic stress. This has been 
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supported by studies showing significantly increased toxicity of Aβ oligomers 
compared to Aβ fibrils [38, 39]. 
Oligomeric Aβ has been shown to recruit inflammatory cytokines which 
induces oxidative stress [40]. This, in turn, is hypothesised to generate NFTs, synaptic 
failure and AD pathology (reviewed in [13]). The theory further suggests that an 
increased ratio of Aβ42 to Aβ40 (Aβ42/Aβ40) generation is a major factor in AD 
neuropathology. This is supported by studies showing that Aβ42 increases plaque 
formation and  neurotoxicity relative to Aβ40, although both exhibit significant 
toxicity to neurons in vitro [41].  In addition, dementia in individuals carrying the 
PSEN1 mutation ( see section 1.2.2)  progresses in a positive correlation with the 
Aβ42/Aβ40 ratio [42].  Epidemiological studies have demonstrated that Aβ-plaques 
correlate strongly with cognitive decline in the entorhinal cortex [43]. Taken together, 




 The first genetic mutation causing EOFAD was found on chromosome 21 in 
the allele encoding the amyloid precursor protein (APP) [44]. The mutation, found in 
a British pedigree known as F23, consists of a dominant mis-sense mutation at 
position 717 of APP and is referred to as the V717I (APP770 numbering) mutation. 
This mutation leads to aberrant APP processing through altering γ-secretase cleavage 
and increasing the Aβ42/Aβ40 ratio [45]. More recently, a study by Muratore et al. 
[46] used neurons taken from inducible pluripotent cells of mutation carriers to show 
that the V717A mutation also alters the subcellular localisation of APP and the total 
and phosphorylated levels of tau.    
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  Generally, EOFAD-associated mutations enhance the generation of toxic Aβ-
peptides from the APP protein through altered γ-secretase action that increases the 
amount of Aβ42 peptide production relative to Aβ40 [45] (see section 1.3.1). Some 
mutations can also affect APP, although these are rare with only 16 recognised APP 
mutations identified to date (reviewed in [37]).  
 EOFAD-associated mutations in γ-secretase have been located on 
chromosomes 14 and 1 within the alleles encoding the γ-secretase components 
presenilins 1 and 2 (PS1 and PS2), respectively. Individuals carrying PS1 or PS2 
mutations exhibit either overall increased Aβ generation or an increase in the 
Aβ42/Aβ40 ratio supporting a ‘gain of function’ hypothesis [37]. A missense mutation 
in PS1 has also been shown to inhibit the autoproteolysis of the protein required for 
the subsequent formation of the enzymatically active heterodimer [47].  
 EOFAD-associated mutations are only present in approximately 0.1% of all 
AD cases, the remainder of them representing sporadic forms of the disease [37]. 
Recent Genome-Wide Association Studies (GWAS) have highlighted several genes 
that confer increased or decreased susceptibility to AD and these are summarised in 
Table 1.2.  The Apolipoprotein E (ApoE) gene seems to be most closely linked to 





1.3. The amyloid precursor protein  
  The first isolation of APP was in 1987 when Kang et al. [49] successfully 
isolated full length APP cDNA through using foetal mRNA and probing for the N-
terminus of the β-amyloid protein. APP is a single-pass, multi-domain, 
transmembrane protein. Alternate splicing of exons 7, 8 and 15 of the APP gene 
generates at least ten known isoforms of the protein; the most common of which are 
695, 751 and 770 residues long [50]. APP695 is expressed principally in the central 
nervous system  (CNS) at levels around 6-10 times greater than the APP751 and APP770 
Table 2.2 The most prevalent gene-disease association risks in late-onset AD. OR; odds ratio, SNP; single 
nucleotide polymorphism Adapted from Sleegers et al[2] and Guerreiro[3] 
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isoforms, which are expressed in both the CNS and peripheral tissue [51]. Unlike 
APP751 and APP770, APP695 lacks a Kunitz-type protease inhibitor (KPI) domain (Fig. 
1.2).  
 The structure of APP comprises a large extracellular domain, a transmembrane 
region and a short C-terminal intracellular domain (Fig. 1.2). Within the extracellular 
domain of the protein there is a conserved E1domain containing a cysteine-rich 
growth factor / heparin binding domain (GFD / HBD) and a copper binding domain 
[52]. This is followed by an acidic domain, the KPI region and the E2 domain. The E2 
domain contains a second heparin binding site [52] which evidence suggests is 
responsible for synaptic growth and stabilisation [53].  
   
 
1.3.1. APP trafficking and proteolysis 
 APP is synthesised on the endoplasmic reticulum (ER) and  transported 
through the Golgi apparatus where it undergoes post-translational modifications 
including O-glycosylation and sulfation [54] before being transported to the neuronal 
axon (Fig. 1.3A). The protein then undergoes fast anterograde transport to the 
synapse. Only around 10% of APP reaches the plasma membrane from the trans-Golgi 
network with most of the protein being proteolytically shed from the cell surface and 
Figure 1.4. Schematic diagram of APP (numbering according to APP770). APP695 does not exhibit a KPI or OX2 domain, 
whilst APP751 does not exhibit an OX2 domain. Adapted from Duce et al. [1].   
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the remainder being re-internalised to lysosomes or early endosomes via targeting to 
clathrin-coated pits involving the YENPTY motif within the APP cytosolic domain 
[55].   
 Proteolysis of APP occurs through two major routes; the amyloidogenic and 
non-amyloidogenic pathways [56] (Fig. 1.3B). The amyloidogenic pathway comprises 
of β-secretase cleavage generating the soluble ectodomain sAPPβ, and a membrane 
anchored C-terminal fragment of 99 amino acids (CTF-99) (Fig. 3B). The latter  
 
Figure 1. 3. APP trafficking (A) and proteolysis (B). (A) Taken from Cheng et al [57]. (1) APP is 
synthesised in the endoplasmic reticulum, then matures along the secretory pathway through the Golgi. 
Once it reaches the cell surface, APP is either processed by the non-amyloidogenic α-secretase or (2) 
re-internalised to the endosomal compartments. Most amyloidogenic processing occurs in the 
endosomal compartments by BACE. (3) The remaining APP is recycled to the Golgi or degraded in the 
lysosomes. (B) The amyloidogenic and non-amyloidogenic processing of APP. During non-
amyloidogenic processing, APP is cleaved by α-secretase within the Aβ domain creating a membrane 
anchored CTF-83 fragment and sAPPα. CTF-83 is subsequently cleaved within the membrane by γ-
secretase, which generates the intracellular AICD and the extracellular p3 fragment. During 
amyloidogenic processing, APP is cleaved by β-secretase generating the membrane anchored CTF-99 
and sAPPβ. CTF-99 is subsequently cleaved by γ-secretase, releasing the AICD intracellularly and the 








fragment is then cleaved by a γ-secretase complex to yield the neurotoxic Aβ-peptides 
characteristic of AD and the APP intracellular domain (AICD). Alternatively, in the 
non-amyloidogenic pathway, APP is cleaved by an α-secretase activity generating a 
soluble ectodomain (sAPPα) and a membrane anchored C-terminal fragment of 83 
amino acids (CTF-83).  
  
1.3.1.1. β-secretase 
 The enzyme responsible for the β-secretase processing of APP was isolated 
almost simultaneously by several groups [58-60] and is now unilaterally referred to as 
beta-site APP-cleaving enzyme 1 (BACE1).  APP is cleaved by the β-secretase 
BACE1 C-terminal to methionine 596 (APP770 numbering) [58]. Vassar et al. [58] 
used a cDNA library to identify BACE1 as a type-1 transmembrane aspartyl protease 
with an active site on the luminal side of the membrane. The same author used 
immunoblotting to reveal that BACE1 was predominantly localised to the Golgi and 
endosomes, whilst it was detected at low levels in lysosomes and the ER. Cells 
overexpressing BACE1 exhibited a two-fold increase in Aβ production and a 
significant decrease in the yield of sAPPα [58]. The in vivo role of BACE1 as a β-
secretase was subsequently confirmed through the use of BACE1 knockout mice 
which exhibited decreased Aβ generation with a reciprocal increase in sAPPα 
production [61].   
 
1.3.1.2. γ-secretase 
 The C99 fragment generated by β-secretase processing of APP is then cleaved 
by the γ-secretase complex at a number of possible positions within the C-terminal 
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region of the Aβ domain [50]. The γ-secretase is a multi-protein complex consisting of 
presenilin 1 or 2 (PS1 or PS2), nicastrin (NCT), Aph1 and presenilin enhancer 2 
(PEN2) [50].  
 PS undergoes autocatalytic proteolysis to generate N- and C-terminal 
fragments that subsequently form an active heterodimer in which the two aspartyl 
residues of the active site are spatially arranged in the correct orientation for the 
cleavage of the APP substrate [47]. Whilst this heterodimer carries the active protease 
component of the γ-secretase complex, NCT, Aph1 and PEN2 bind to the complex 
regulating its conformation and, therefore, activity [62].  
 Amongst other transmembrane substrates, γ-secretase complexes are also 
responsible for the proteolysis of Notch receptors; in fact the parallels between APP 
and Notch proteolysis originally led to the proposal of a signalling role for the AICD 
[62, 63]. The AICD has subsequently been shown to alter the expression of a range of 
proteins including APP itself (discussed in more detail in section 1.4.2.). 
 The subcellular localisation of γ-secretase-mediated APP proteolysis remains 
controversial although recent research using green fluorescent protein-tagged APP has 
demonstrated that the bulk of this processing occurs in the early endosomes or surface 
membrane with little activity in the early secretory pathway [63]. An important 
regulatory aspect of both β- and α-secretase APP processing is the co-localisation of 
the enzymes and substrate within lipid rafts. These are areas of the membrane 
enriched in cholesterol, saturated fatty acids and phospholipids such as 
phosphatidylinositol and phosphatidylserine carrying saturated fatty acyl chains [64, 
65]. In fact, multiple groups have demonstrated a role for lipid rafts in the 





 The α-secretase activity cleaves APP between lysine 16 and leucine 17 of the 
Aβ domain thereby precluding the formation of intact neurotoxic peptides. The first 
clues as to the identity of the enzyme came when Roberts et al. [67] used a crude 
membrane preparation to determine that α-secretase was an integral membrane 
protease and a member of the zinc metalloprotease (ZMP) family. Subsequently, 
several members of the ADAM (a disintegrin and metalloproteinase) subgroup of 
ZMPs have been implicated as possible α-secretases including ADAMs 9, 10 and 17 
(reviewed in [56]). Perhaps the most widely implicated of these is ADAM10 which 
exhibits both basal and regulated (i.e. phorbol ester-stimulated) α-secretase activity 
[68]. Postina et al. [69] found an increase in sAPPα levels with a subsequent decrease 
in sAPPβ and Aβ plaques in mice overexpressing ADAM10, providing the first in 
vivo evidence that ADAM10 is the primary α-secretase. The same study showed a 
reverse of these results in mice expressing inactive ADAM10. In humans, low levels 
of ADAM10 expression in platelets are associated with low cerebrospinal fluid (CSF) 
levels of sAPPα in AD patients [70]. 
 Early research into the non-amyloidogenic processing of APP indicated that α-
secretase was located within the plasma membrane and that APP must travel to the 
cell surface before undergoing non-amyloidogenic proteolysis [71]. Whilst the cell 
surface is still considered the major site of α-secretase activity, small amounts have 





1.4. The physiological roles of APP and its derivatives 
 
1.4.1.  Full-length APP and sAPPα 
 Full-length APP has been found to interact with collagen, laminin and heparin 
which all mediate cell adhesion [72-74].  Furthermore, APP, APLP-1 and APLP-2 
have been shown to form dimers and multimers both in vivo and in vitro and interact 
both at the cell surface and intracellularly suggesting a role for this self-association in 
cell adhesion [75].  
 APP has also been strongly implicated in trophic functions with APP-deficient 
neurons exhibiting decreased survival, axonal branching and minor process production 
[76]. The trophic role of APP is thought to be related, at least in part, to the generation 
of sAPPα which has been found to mediate synaptic growth via a process involving 
the 'RERMS' motif within the fragment [52]. Clearly, APP has a role to play in brain 
development and function as, despite being viable and fertile, APP knockout mice 
show a 10% decrease in brain weight and exhibit significant hippocampal 
abnormalities along with spatiotemporal learning consistent with impaired long term 
potentiation [77]. The lack of a more severe phenotype exhibited by APP knockout 
mice is thought to be due in part to a compensatory role played by APLP-1 and/or 
APLP-2. Indeed, triple knockout (APP, APLP-1 and APLP-2) mice die shortly after 
birth and show significant synaptic abnormalities [78]. Synaptic terminals in 
APP+APLP2 knockout mice are incorrectly juxtaposed suggesting that the APP gene 
family is essential in synaptogenesis [77].  
  sAPPα, in particular, is thought to exhibit a neuroprotective function 
and recent findings that this fragment reduces expression of CDK-5 (a kinase that 
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induces neurodegeneration and indirectly increases amyloidogenic processing of APP) 
provide a potential mechanism for its neuroprotective properties [79].  
 
1.4.2.  AICD 
 Both the AICD and Notch intracellular domains co-localise to nuclear spots 
and form transcription complexes with Fe65 and Tip60 [80]. In fact, both fragments 
can influence the expression of a range of proteins (Table 1.3). Of particular relevance 
to AD is the fact that AICD expression has been linked to both increased APP mRNA 
levels and decreased APP half-life suggesting that, whilst the fragment enhances APP 
transcription, it may also promote the transcription of genes regulating the turnover of 
the APP protein [81].  
Table 1.2. AICD target genes. Adapted from Pardossi-Picquard & Checler [54]. 




 Metastasis suppressor, apoptosis 






 Cell adhesion, synaptogenesis, 
neurite outgrowth 
 APP cleavage 











 Cell cycle proliferation, 
differentiation, survival 
 Endocytosis and signalling, 




1.4.3.  Aβ-peptides 
 In contrast to the neurotoxic effects of Aβ-peptides associated with AD, 
picomolar concentrations of Aβ42 significantly improved both long-term potentiation 
and multiple hippocampal-mediated memory functions in mice transfused with the 
peptide [82]. This supports a physiological role for lower Aβ concentrations in long-
term potentiation that is perhaps lost in AD.  
 
1.5. Copper, Alzheimer's disease and APP 
 Copper is a trace element essential to human life. It serves as an allosteric 
regulator or catalytic cofactor in many metalloenzymes including cytochrome c 
oxidase, lysyl oxidase, ceruloplasmin, superoxide dismutase and catechol oxidase. 
These enzymes are critical in the normal function of bodily processes such as 
mitochondrial respiration, antioxidant defence, biometal transport and connective 
tissue formation. Copper further acts as a transcriptional regulator for metal 
responsive Ace1, Amt1 and Mac1 genes, which control intracellular accumulation of 
transition metals [83]. 
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 Humans consume 0.6-1.6 mg  of copper a day which originates from pulses, 
nuts, grains and shellfish [84]. However, high concentrations of copper are extremely 
toxic due to the ability of the metal to generate ROS via Fenton’s chemistry, 
contributing to oxidative stress and the oxidation of lipids, nucleic acids and proteins 
[85]. Therefore, humans have developed complex copper homeostatic mechanisms. 
 In mammals, copper uptake occurs in the enterocytes of the digestive tract and 
the liver via the copper plasma membrane transporter 1 (CTR1). Chaperone proteins 
transport copper to the copper transporters ATP7A (enterocytes) and ATP7B (liver) 
where copper is released into the portal vein or blood stream for uptake by the body 
[83]. Excess copper is re-transported into the intestinal epithelium or into bile for 
Figure 1.4. Simplified uptake of copper into cells. The majority of circulating copper is bound to 
Ceruloplasmin (CP). Copper enters the cell via the transporter CTR-1 and binds to the chaperones COX17, 
ATOX1 and CCS. COX17 facilitates the transport of copper to the mitochondria, where it interacts with the 
SCO proteins to transport copper to cytochrome-c oxidase (COX), which is essential for normal mitochondrial 
function. CCS transfers the copper to superoxide dismutase (SOD1) which is an antioxidant. ATOX1 
transports copper to the ATP7A/ATP7B in the Golgi. ATP7A transports copper back into the blood whilst 









excretion (Fig. 1.4). The majority of circulating copper is bound to ceruloplasmin 
(approximately 65% of the total copper) or albumin (approximately 18%) [86, 87]. 
Copper uptake across the blood-brain-barrier is reportedly mediated by ATP7A 
transporters [85]. 
 The importance of copper homeostasis is demonstrated through diseases 
related to defective copper transport such as Menkes disease in which a mutation 
within the ATP7A transporter impairs the absorption of copper from the intestinal 
tract and its transport into the blood stream [88]. This manifests as extreme copper 
deficiency with associated neurodegeneration and connective tissue abnormalities. 
Similarly, Wilson's disease, a disorder of the ATP7B transporter, results in the 
impaired excretion of copper from the liver causing liver cirrhosis and elevated free 
copper concentrations in the blood leading to ROS generation [88]. 
 
1.5.1.  Copper and Alzheimer's disease 
 Pajonk et al. [89] demonstrated that cognitive test scores in AD patients 
negatively correlated with plasma copper concentrations indicating that copper 
deficiency may be linked to the disease. Conversely, Smorgon et al. [90] 
demonstrated a significantly higher serum copper centration in AD patients compared 
to age-matched controls. Although research of this type has been consistently 
disparate, a meta-analysis study did find a small but significant increase in copper 
concentrations in the blood and cerebrospinal fluid of AD patients compared with 
controls [91]. 
 In terms of brain tissue, significant decreases in copper concentration have 
been demonstrated in the amygdala and hippocampus of AD patients with lower, but 
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not significantly different, concentrations in other areas of the brain [92]. In apparent 
contrast, Religa et al. [93] found a higher copper concentration specifically in the 
neuropil of the amygdala suggesting that copper was transported out of the cells more 
effectively in AD patients. Collectively, these studies, although partially 
contradictory, nonetheless demonstrate a complex inter-relationship between copper 
homeostasis and AD. 
 
1.5.2. Copper and APP expression 
 Copper has been implicated in the regulation of APP transcription, translation 
and proteolysis in multiple studies. Cater et al. [94] demonstrated a reduction of APP 
mRNA expression under copper deficient conditions in fibroblasts expressing mutant 
ATP7A / ATP7B transporters. However, the authors showed that APP protein 
expression remained stable suggesting that copper deficiency enhanced the translation 
efficiency of APP mRNA. Similarly, Armendariz et al. [95] demonstrated a 2.2-fold 
increase in APP expression through chronic copper dosing of primary neurons. 
Bellingham et al. [96] demonstrated an 80% reduction in APP promoter activity when 
the -490 to +104 region of the APP promoter was deleted. The same study also found 
that copper levels positively correlate with APP levels, supporting findings by 
Armendariz et al. [95]. Taken together, these studies promote the existence of a 
copper responsive element in the -490 to +104 region of the APP promoter that 
increases APP transcription in increased copper concentrations.  
 In vivo studies in APP knockout mice show a 40% increase in copper 
concentrations in the cerebral cortex compared to WT mice [97]. The authors 
proposed that low antioxidant defence in neurons results in the tight regulation of 




1.5.3. Copper and APP proteolysis / trafficking 
 Copper has been shown to decrease Aβ generation and enhance the non-
amyloidogenic production of sAPPα at metal concentrations as low as 10 μM [98]. 
Similarly, Cater et al. [94] showed a significant switch from sAPPα to sAPPβ 
secretion in a copper-deficient cell model. 
 In terms of APP trafficking, studies using a C-terminally fluorescent-tagged 
form of APP demonstrated a 2-fold increase in cell surface levels of the protein 
following the treatment of SH-SY5Y cells with copper [99]. The enhanced cell 
surface levels of APP were accompanied by a reduction in Golgi-associated protein 
and its increased exocytosis. 
 Lipid rafts have also been linked to copper and APP trafficking/proteolysis. 
Hung et al. [100] found that increased copper levels correlated inversely with γ-
secretase localisation to lipid rafts and that copper promoted the cell surface 
localisation of APP, which increases non-amyloidogenic APP processing. The same 
study found that copper levels exhibited an inverse relationship with lipid raft copper 
concentrations. This suggests that copper deficiency both increases amyloidogenic 
processing and co-localises Aβ to copper in lipid rafts, facilitating the formation of 
pro-oxidant Aβ:Cu (II) complexes that contribute to oxidative stress [100].  
1.5.4. APP and the regulation of copper toxicity 
 The fact that APP is known to reduce Cu (II) to Cu (I) [101] has led to much 
research investigating whether the protein can regulate copper-induced toxicity in 
cells. The enhanced expression of APP in cells expressing mutant ATP7A / ATP7B 
transporters (which exhibit a 5-fold increase in intracellular copper levels) indicates 
that the former protein is indeed involved in the cellular response to elevated copper 
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[95]. The cytoprotective role of APP against copper is further supported by the 
experiments of Cerpa et al. [102] which demonstrated that peptides mimicking the E1 
copper binding domain of APP protected mice against the spatial memory impairment, 
neuronal cell loss and astrogliosis caused by the injection of copper chloride into their 
brains. No such protection was observed when a similar peptide lacking crucial 
copper-binding histidine residues was employed. 
 However, conversely, other studies suggest that APP actually facilitates 
copper-induced toxicity. White et al. [35] demonstrated that neurons from APP 
knockout mice were more resistant to copper toxicity than their counterparts 
expressing normal APP levels. The same group also showed that, when the APP 
knockout neurons were treated with a peptide mimicking the APP E1 copper binding 
domain, copper-induced toxicity was increased. White et al. [103] also demonstrated a 
peroxidising capability of full-length APP that is also present in APLP2 and non-
human orthologues. 
 
1.5.5. APP and Aβ aggregation / clearance 
 Although high levels of copper (400 μM) are present in senile plaques [104] it 
is unclear whether it is metal binding that promotes Aβ aggregation or whether the Aβ 
aggregates, once formed, sequester metal. The former possibility is supported by 
evidence that Aβ fibrillisation is accelerated by trace concentrations of both copper 
and zinc (≤0.8 μM); an effect that was negated in the presence of a metal chelator 
[105]. Conversely, Innocenti et al. [106] used atomic force microscopy to demonstrate 
that low copper and zinc concentrations (0.1-1 μM)  stabilized non-fibrillar Aβ 
oligomers. Similarly, Curtain et al. [107] showed that copper promoted a change in 
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Aβ conformation from β-sheet to α-helix thereby supporting oligomer rather than 
fibril formation. 
 The second possibility, i.e. that Aβ aggregates sequester copper, is supported 
by the observation that Aβ aggregates bind Cu(II) with an affinity two orders of 
magnitude higher than that observed for Aβ monomers facilitating the sequestration of 
the metal from albumin [108]. This high affinity was attributed to a co-ordination 
sphere of a total of three histidine residues contributed by two adjacent Aβ peptides.  
 Recently, Singh et al. [109] suggested that copper accumulation in the brain 
might impair the clearance of Aβ across the blood-brain-barrier by the low density 
lipoprotein receptor-related protein 1 (LRP1). The authors showed that chronic copper 
dosing in young mice enhanced Aβ levels in the brain with a concomitant decrease in 
levels of LRP-1. Furthermore, LRP-1 deficient mice exhibited increased brain Aβ 
levels and neuroinflammation. 
 
1.5.6. Copper and the mediation of Aβ neurotoxicity 
 Both Aβ40 and Aβ42 are known to stimulate ROS production, lipid 
peroxidation and DNA oxidation (reviewed in [110]), and it is possible that copper 
binding to Aβ mediates this process. Aβ peptides bind to Cu(II) with a stoichiometry 
of 1:1 [111]. Huang et al. [112] found that Aβ binds Cu (II) and reduces it to Cu (I), 
generating the potent oxidiser hydrogen peroxide. The reducing potential of the Aβ 
molecule was subject to its length, with Aβ42 exhibiting the greatest reducing 
potential. In their following paper, Huang et al. [113] demonstrated that the reduction 
of Cu (II) by Aβ was directly responsible for the generation of hydrogen peroxide 
through an electron transfer chain that facilitated the reduction of oxygen. Further 
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studies have confirmed the ability of Aβ to generate hydrogen peroxide, which 
consequentially generates hydroxyl radicals in vitro (reviewed in [114]). Taken 
together, these studies confirmed that Aβ:Cu complexes generate ROS that may 
induce the neurotoxicity observed in AD. 
 
1.5.7. APP as a copper binding protein 
 In addition to the binding of copper to Aβ (it is not clear whether the metal 
binds this region in the full-length APP protein) APP possesses at least two other high 
affinity copper binding domains within the extracellular E1 and E2 domains. 
 
1.5.7.1. The E1 copper binding domain 
 The E1 CuBD is located between amino acids 28 and 129 of APP [1]. The 
structure of the domain has been solved by nuclear magnetic resonance spectroscopy 
and X-ray crystallography and comprises an α-helix packed against three anti-parallel 
β-strands [115]. The putative binding site consist of histidines 147 and 151, tyrosine 
168 and an axial water and equatorial water molecule which together form a 
tetrahedrally distorted square planar geometry when bound [115]. This binding site is 
referred to as a Type 2 non-blue Cu centre due the involvement of histidine nitrogen 
ligands and oxygen ligands. Methionine 170 is thought to act as an electron donor in 
the reduction of Cu(II) to Cu(I), and the surface localisation and Type 2 centre further 
support a role for this CuBD in the redox cycling of Cu(II) to Cu(I) [116].  
 A study examining the potential role of the E1 CuBD in APP cell biology 
demonstrated decreased APP maturation, ER to Golgi trafficking and folding when 
histidine residues 149 and 151 were mutated to asparagine [117]. The relevance of the 
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replacement of histidine to asparagine is biologically debateable as the latter is rarely 
found in helical structures [118] (in which the copper co-ordinating histidine residues 
of the E1 CuBD are located) and is likely to disrupt such secondary structure.  
 
1.5.7.2. The E2 copper binding domain 
 The E2 copper binding domain of APP is located between residues 295 and 
500 of the ectodomain (APP695 numbering) [119]. X-ray crystallography of the APP 
E2 domain demonstrated a structure consisting of four α-helices surrounding a 
hydrophobic core. Using cadmium ions as markers of potential metal binding sites, 
Dahms et al. [119] identified a well-conserved potential copper binding site comprised 
of four histidine residues at positions 313, 382, 432 and 436 (APP695 numbering) from 
the α-B, α-C and α-D helices which coordinate around a ‘tetrahedrally distorted square 
planar’ structure when bound. The authors demonstrated an upper limit dissociation 
constant of Kd ≤ 13 nM for copper binding to this site and demonstrated that copper 
(or zinc) binding to the APP E2 CuBD caused a significant conformational change in 
domain structure. Furthermore, limited proteolysis experiments demonstrated that the 
structure of the full-length APP protein was more resistant to degradation when bound 
to copper within the E2 domain. 
 
1.6. Aims of the current project 
 Although copper is now known to bind to the E2 domain of APP, no studies 
have examined the effects of this binding on the cell biology of the protein. In the 
current study, histidine to alanine mutant constructs (within the E2 CuBD) will be 
used in order to study any potential effects of metal binding within this domain on the 
following aspects of APP cell biology: 
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(i) APP expression and proteolysis. 
(ii) The effect of E2 copper binding on copper-induced cytotoxicity. 









































 All tissue culture reagents were purchased from Lonza (Basel, Switzerland) 
and all other reagents, unless otherwise stated, were purchased from Sigma-Aldrich 
(Poole, U.K.). pIREShyg mammalian expression vector was from Invitrogen (Paisley, 
U.K.). The APP695-pIREShyg vector has been described previously [120] and was 
used, by Epoch Biolabs (Texas, U.S.A.) as a template to generate histidine to alanine 
APP substitution mutants as described in the Results section. 
 Anti-APP C-terminal polyclonal antibody, anti-actin monoclonal antibody and 
secondary peroxidase-conjugated antibodies were from Sigma-Aldrich (Poole, U.K.). 
Anti-APP 6E10 monoclonal antibody was from Covance (Princeton, U.S.A.) and the 
anti-APP polyclonal antibody used in the immunofluorescence studies was from 
Abcam (Cambridge, UK). The anti-sAPPβ 1A9 monoclonal antibody was kindly 
provided by Prof. Nigel Hooper (Manchester, U.K.). 
 
2.2. Methods 
2.2.1. Bacterial transformation 
 DNA (approximately 1 μg) was incubated with 20 μl of XL-1 Blue competent 
E.Coli (Agilent Technologies, Stockport, UK) for 20 min at 4
o
C. The cells were then 
heat shocked at 42˚C for 45 sec and then incubated at 4 oC for an additional 2 min. 
 
2.2.2. Preparation of agar plates and bacterial culture 
 Liquid broth (LB) was prepared by dissolving 10 g of low salt granulated broth 
(Melford, Ipswich, U.K.) in 500 ml of distilled water. Agar (Melford, Ipswich, U.K.) 
(5 g) was added to the LB and the solution was then autoclaved for 30 min. After 
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cooling to 40 
o
C, ampicillin stock (100 mg ml
-1
) was added to the agar to a final 
concentration of 50 μg ml-1. Plates were then poured, allowed to cool and stored 
inverted at 4 
o
C until use.  
 Transformed cells (10 μl) were streaked onto an agar plate and cultured 
overnight at 37 
o
C. Colonies were then stabbed and transferred to 50 ml of LB 
containing 50 μg ml-1 ampicillin that had been autoclaved previously in conical flasks. 
These 'midi-cultures' were grown at 37 
o
C on an orbital shaker overnight. 
 
2.2.3. DNA purification 
 The contents of a single midi-culture (see section 2.2.2. above) were 
centrifuged at 6000 g for 15 min and DNA was purified from the pellets using the 
Qiagen® Plasmid Midi Purification Kit according to the manufacturer's protocol. 
DNA concentrations were determined using the NanoDrop®2000 spectrophotometer, 
and the DNA was stored at -20 ˚C. 
 
2.2.4. Ethanol precipitation of DNA 
 DNA prepared as described above was combined with 1/10 volume of 3 M 
sodium acetate (pH 5.2) and two volumes of cold absolute ethanol. This mixture was 
then incubated at -20 
o
C for 1 h prior to centrifuging for 20 min at 11,600 g at 4 
o
C. 
The supernatant was removed and replaced with 300 μl of 80% (v/v) ethanol without 
disturbing the pellet. The sample was then centrifuged once more under the same 
conditions for 5 min. The supernatant was removed again and the DNA was 




2.2.5. Mammalian cell culture 
 Human neuroblastoma, SH-SY5Y, and human embryonic kidney (HEK) cells 
were cultured in Dulbecco’s Modified Eagle’s medium (DMEM) high glucose with L-
glutamine, supplemented with 10%, (w/v) foetal bovine serum, penicillin (100 units 
ml
-1
) and streptomycin (100 μg ml-1). The cells were grown in 5% CO2. Once 
confluent, cells were washed with 2 ml trypsin before replacing with a fresh 2 ml and 
incubating at room temperature until the cells were released from the flask base. The 
trypsin was then deactivated by the addition of complete growth medium (10 ml). 
Cells were then pelleted by centrifugation for 3 min at 1500 g and resuspended in the 
appropriate volume of complete growth medium prior to seeding at the required 
density.  
For long term storage, cell pellets were resuspended in 1 ml complete growth 
medium containing 10% (v/v) dimethyl sulfoxide (DMSO). The cells were transferred 
to cryovials (Corning, New York, U.S.A.) and snap frozen in liquid nitrogen.  
 
2.2.6. Transient transfection of HEK cells 
 The following procedures were all performed under aseptic conditions. HEK 
cells were grown to 80% confluence at which point the growth medium was removed 
and cells were washed in situ with 10 ml UltraMEM™. A fresh 10 ml of 
UltraMEM™ was then added to the cells and they were incubated for 30 min at 37 oC 
in 5% CO2. During this incubation period, 8 μg of ethanol precipitated DNA (see 
section 2.2.4 above) was diluted to 500 μl using UltraMEM™. A second solution was 
also made consisting of 20 µl Lipofectamine®2000 (Life™ Technologies, Carlsbad, 
U.S.A.) and 480µl UltraMEM™. These two solutions were incubated for 5 min at 
room temperature, combined and then incubated for a further 20 min at the same 
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temperature. During this time the medium was removed from the cells and replaced 
with a fresh 2 ml of UltraMEM™. The DNA: Lipofectamine®2000 complexes were 
then added drop-wise to the cells with constant gentle swirling. The cells were 
returned to the growth incubator for 5 h after which 5 ml of DMEM containing 30% 
(v/v) FBS (no penicillin or streptomycin) was added to each flask. The cells were then 
cultured for an additional 24 h followed by the removal of spent medium and its 
replacement with 10 ml of complete growth medium. Following an additional 24 h 
incubation the transfectants were ready to use for experiments. 
 
2.2.7. Stable transfection of HEK and SH-SY5Y cells 
 For stable transfections, 8 μg (Lipofectamine® protocol) or 20 μg 
(electroporation protocol) of DNA was linearized in a solution consisting of DNA, 
Ahd1 restriction enzyme (3 μl), 10 x restriction buffer (5 μl), BSA (1 mg ml-1) and 
distilled water to make up to 50 μl. After overnight incubation at 37 oC, the DNA was 
ethanol precipitated as described in section 2.2.4. 
 HEK cells were then stably transfected using the lipofectamine method 
described above (section 2.2.6.). Stable transfectants were then selected by culturing 
the cells in the presence of hygromycin B (150 μg ml-1) (Invitrogen, Paisley, U.K.). 
 SH-SY5Y cells were stably transfected by electroporation. Cells were grown 
to 60% confluence before trypsinising as described in section 2.2.5. The cell pellets 
were resuspended in 800 µl UltraMEM™ and transferred to a 2 mm mammalian 
transfection cuvette (Bio-Rad, Hemel Hempstead, UK) along with the ethanol 
precipitated DNA in a volume of 30 μl. Following thorough mixing by repeat 
pipetting, the cells were subjected to electroporation (square wave programme, 120 V, 
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25 ms) using a Gene Pulser Xcel™ electroporator (Bio-Rad, Hemel Hempstead, 
U.K.). The cuvette was then transferred to ice for 10 min before mixing the contents 
of the cuvette thoroughly with 5 ml complete growth medium. The cells were then 
transferred to 10 ml complete growth medium in culture flasks and grown to 
confluence before selecting stable transfectants using hygromycin B as described 
above. 
 
2.2.8. Preparation of cell lysates and conditioned medium samples 
 Following cell treatments, conditioned medium was removed and centrifuged 
for 5 min at 1500 g. The supernatant was then transferred to an Amicon Ultra-15 
Centrifugal Filter Unit (Millipore, Watford, U.K.) which, prior to use, had been 
equilibrated in distilled water  (10 ml) for 10 min. The supernatant was centrifuged at 
3000 g (4 
o
C) until the volume was reduced to approximately 400 μl. Protein 
concentrations were determined (see section 2.2.9) and the samples were equalized in 
terms of protein by diluting with distilled water before freezing at -20 
o
C pending 
further use.  
For the preparation of cell lysates, the cells were washed in situ using 20 ml of 
phosphate-buffered saline (PBS; 1.5 M NaCl, 20 mM NaH2PO4, 200 mM Na2HPO4 
made up in distilled water, pH 7.4). The cells were then scraped from the flasks into a 
fresh 10 ml PBS and transferred to a Falcon tube. Flasks were rinsed with an 
additional 5 ml PBS which was transferred to the same Falcon tube. Cells were 
pelleted by centrifugation at 1500 g (3 min) before removing the supernatant and 
resuspending the cells in 2 ml of lysis buffer (0.1 M Tris, 0.15 M NaCl, 1% (v/v) 
Triton X-100, 0.1% (v/v) Nonidet P-40, pH 7.4) containing 10 mM 1,10-
phenanthroline. After resuspension, the cells were sonicated for 30 sec using a probe 
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sonicator (MSE, Crawley, U.K.) and the lysates were transferred to Eppendorf tubes 
and centrifuged at 11,600 g for 10 min. The supernatants were then assayed for 
protein (see section 2.2.9) and the samples were equalized in terms of protein by 
diluting with lysis buffer. The final lysate preparations were then frozen at -20 ˚C 
pending further analysis. 
 
2.2.9. Bicinchoninic acid (BCA) protein assay 
 The BCA protein assay was performed using bovine serum albumin (BSA) 
standards made up in distilled water and loaded (10 μl) into a 96-well microtitre plate 
as shown in Table 2.1. Samples of cell lysates (3 μl) or concentrated conditioned 
medium (5 μl) were loaded in duplicate starting at row B on the plate. Assay reagent 
(a 50:1 (v/v) ratio of BCA stock solution (Pierce, Illinois, U.S.A.) and 4% (w/v) 
CuSO4. 5H2O) was then added (200 μl) to all wells (standards and samples) and the 
plate was incubated for 30 min at 37 ˚C. Absorbances of the samples were read at 570 
nm using a PerkinElmer VIKTOR™ plate reader. A BSA standard curve was 










Table 2.1. BSA standards and their loading in 96 well plates. 
 
 
2.2.10. Sodium dodecylsulphate-polyacrylamide gel electrophoresis (SDS-PAGE) 
 Protein samples (20-40 μl) were denatured by the addition of 0.5 volumes of 
dissociation buffer (10% (w/v) SDS, 80 mM dithiothreitol, 20% (v/v) glycerol, 140 
mM Tris-HCl pH 6.8, few drops of 0.05% (w/v) bromophenol blue) and subsequent 
boiling for 3 min. Molecular weight standards (GE Healthcare, Buckinghamshire, 
U.K.) were prepared in the same way, without the subsequent boiling. 
 Equal volumes of protein-equalized samples were then resolved on 5-15% or 
7-17% polyacrylamide gradient gels. The stacking and resolving gels were prepared 
according to the recipes detailed in Table 2.2. 
 
Standard [BSA] (mg/ml) Wells loaded 
A 0.2 A1 and A2 
B 0.4 A3 and A4 
C 0.6 A5 and A6 
D 0.8 A7 and A8 
E 1.0 A9 and A10 




Prior to the addition of TEMED, the solution was vortexed briefly and poured using a 
gradient mixture with a peristaltic pump. Once poured water-saturated isobutanol was  
pipetted over the top layer of the gel to eliminate any air bubbles and provide a marker 
of when the gel had set, and the gel was left for at least 15 minutes. Once set the 
water-saturated isobutanol was poured off the gel, washed with ddH20, and the 
Table 2.2. SDS-PAGE resolving and stacking gel constituents. 
 Resolving gel solutions Stacking 
gel 
Reagent 17% 7% 15% 5%  
Sucrose 0.37 g - 0.33 g - - 
Tris/HCl pH 8.8 1.39 ml 1.39 ml 1.39 ml 1.39 ml - 
Tris/HCl pH 6.8     0.63 ml 
30% acrylamide, 0.8% Bis 
(Universal Biologicals, 
Cambridge, U.K.) 
2.1 ml 0.88 ml 1.9 ml 0.63 ml 0.5 ml 
Distilled water - 1.36 ml 0.22 ml 1.64 ml 3.83 ml 
1.5% (w/v) ammonium 
persulphate 
0.22 ml 0.1 ml 0.2 ml 71 µl 0.25 ml 








stacking gel was pipetted onto the gel following the above protocol. This was left to 
set for a further 15 minutes. 
Protein samples were denatured for 3 minutes at 95°C to stabilise the proteins for 
electrophoresis. Disassociation buffer was added to the samples at half the volume of 
the sample. Gels were loaded onto the electrophoresis tank and filled with running 
buffer (1x Tris/glycine/SDS, Geneflow Ltd, Fradley, UK).  Pre-diluted protein ladder 
(GE Healthcare, UK) was also diluted with denaturing buffer at the same 
concentration as the samples and 20µl added to the initial well, followed by 20µl of 
each sample. Gels were run at 300V in running buffer (0.25 M Tris, 1.92 M glycine, 
1% (w/v) SDS, diluted with distilled water from a 10 x stock) (Geneflow Ltd, Fradley, 
U.K.) at 35 mA per single gel constant current until the dye front reached the bottom 
of the gel.  
 
2.2.11. Western blotting 
 Following SDS-PAGE, resolving gels were transferred to Immunobilon-P 
PVDF (polyvinylidene fluoride) membranes (Millipore, Massachusetts, U.S.A.) in 
Towbin buffer (800 ml methanol, 20 mM Tris, 150 mM glycine, made up to 4 L with 
distilled water) at 115 V for 1 h. 
 Membranes were then washed with PBS for 5 min and blocked for 1 h in 5% 
(w/v) Marvel milk powder in PBS + 0.1% (v/v) TWEEN-20 (PBS-TWEEN). The 
membranes were then washed once more for 5 min in PBS and incubated overnight 
with shaking (4
o
C) in primary antibody at the dilutions described in Table 2.3 made 
up in PBS-TWEEN + 2% (w/v) BSA . The following morning, the membranes were 
washed for 1 x 1 min and 2 x 15 min in PBS-TWEEN. The appropriate secondary 
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antibody (see Table 2.3.) was then incubated with the membranes for a further 1 h at 
room temperature before washing them in PBS lacking Tween (1 x 1 min, 2 x 15 
min). ECL Western blotting substrate (ThermoFisher Scientific, Cramlington, UK.) 
was added to the membrane for approximately 2 min before developing the blot by 
exposure to X-ray film (ThermoFisher Scientific, Cramlington, UK.). Developed blots 
were stained for 2 min in amido black (40% (v/v) methanol, 10% (v/v) acetic acid 
0.01% (w/v)  amido black in distilled water), to visualise bound proteins. 
2.2.12. Stripping and re-probing immunoblots for anti-actin 
Membranes were incubated at 50 ˚C for 30 min in stripping buffer (100 mM β-
mercaptoethanol, 2% (w/v) SDS, 62.5 mM dd H2O, pH6.7) to remove bound proteins. 
Following two 10 min washes in PBS-TWEEN, the immunoblots were then blocked 
and processed as described previously (section 2.2.11). 
 










Anti-APP C-terminal 1:7500 
Anti-APP 6E10  1:2500 
Anti-sAPPβ 1A9 1:3000 
Anti-actin 1:5000 
Anti-Mouse IgG–Peroxidase Antibody raised in 
rabbit 
1:4000 





2.2.13. Copper toxicity assays 
 Cells were grown in T75 cm
2
 flasks until they reached ultra-confluency to 
ensure subsequent seeding at the same densities. Following trypsinization, the cell 
pellets were resuspended in complete growth medium (10 ml). Cells (100-150 μl 
according to cell line) were then seeded in 1 ml of DMEM in the wells of a 24-well 
plate. Cells were grown to confluency before removing the spent growth medium and 
washing the cells with UltraMEM™ (1 ml). The UltraMEM™ was then replaced with 
a fresh 1 ml of the same medium containing the desired final concentrations of copper 
(achieved by adding the appropriate volume of a filter-sterilized 10 mM CuSO4 
solution or 100mM CuCl2:glycine complex stock solution ). The cells were then 
cultured for 48 h after which the medium was removed and the cells were washed 
with UltraMEM™ (1 ml) before replacing this with a fresh 500 μl of the same 
medium. CellTiter 96® AQueous One Cell proliferation Assay solution 
(methanethiosulfonate; MTS) (100 μl) was then added to each well and the plate was 
incubated at 37°C until a colour change was observed. The contents of each well were 
transferred to a 96 well plate to read the absorbance (490 nm). 
2.2.15. Immunofluorescence 
 Cells were grown to 80% confluence on coverslips placed in the wells of a cell 
culture plate. The coverslips were then transferred to a fresh culture plate and washed 
(2 x 5 min) in PBS. The cells were then fixed by the addition of either absolute 
methanol or 3% (w/v) paraformaldehyde, pH 7.4 and subsequent incubation at room 
temperature for 10 min. Each coverslip was then incubated in immunofluorescence 
(IF) buffer (0.025% (w/v) SDS, 0.1% (v/v) Triton, 1% (w/v) BSA in PBS) for 1 h at 
room temperature. Primary anti-APP antibody (ab15272) (Abcam, Cambridge, UK) 
was then diluted at 1:100 in IF buffer prior to centrifugation for 5 min at 11,600 g. 
The antibody supernatant (300 μl) was then added to the cells (after removing the last 
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IF buffer wash) and the plate was wrapped in tin foil and incubated overnight on an 
orbital shaker at 4 
o
C. The following morning, the cells were washed (1 x 1 min and 2 
x 15 min) in PBS-TWEEN. Anti-Rabbit IgG-FITC antibody (Sigma Aldrich, Poole, 
UK) was diluted to 1:300 in IF buffer and centrifuged as per the primary antibody 
before adding 300 μl to each coverslip (after removal of the final PBS-TWEEN wash). 
After a 1 h incubation on the orbital shaker at room temperature, the secondary 
antibody was removed and the coverslips were washed in 200 μl of 4',6-diamidino-2-
phenylindole (DAPI) in PBS  (1:1000) for 5 min in order to optimise nuclear staining. 
Final washes of the coverslips for 1 x 1 min and 2 x 15 min were performed in PBS. 
The coverslips were then removed from the wells of the plate and placed face down 
onto slides with a drop of VECTASHIELD® with DAPI in order to prevent cell 
bleaching. Cells were visualised by confocal microscopy (Zeiss, Cambridge, UK) 
using 405 nm and 561 nm excitation wavelengths. 
 
2.2.16. Statistical analysis 
Statistical analysis was performed using the Student’s t-test. Differences were 
recognised as significant with a P-value of ≤0.05 (*) or ≤0.005 (**). For all results 


























 As already discussed, Dahms et al. [119], identified a copper binding site 
within the E2 domain of APP. The authors demonstrated that the co-ordination of 
copper within this site involved four histidine residues at positions 313, 382, 432 and 
436 (APP695 numbering). However, the same group did not examine the effect of these 
residues on the cell biology of APP; something that clearly has relevance to AD 
pathogenesis. Therefore, in the current study, APP695 mutants containing histidine to 
alanine substitutions within the E2 CuBD have been employed in order to study the 
effects of this domain on the expression, proteolysis and localisation of APP. The 
possible role of the E2 CuBD in regulating cytotoxicity has also been examined. 
 Five APP695 mutant constructs were employed in which the APP coding DNA 
was inserted into the mammalian expression vector pIREShyg (Invitrogen, Paisley, 
U.K.). These constructs consisted of single histidine to alanine substitutions at 
positions 313, 382, 432 or 436 named APP-E2 CuBD H313A, APP-E2 CuBD H382A, 
APP-E2 CuBD H432A and APP-E2 CuBD H436A. A fifth construct contained all 
four of these substitutions, APP-E2 CuBD AAAA (Fig. 3.1.) 
 
3.1. Transient expression and proteolysis of constructs in HEK cells 
 In order to validate the mutant APP constructs they were initially transiently 
expressed in HEK cells. This was a relatively quick method that did not necessitate 
the weeks of antibiotic selection required for the generation of stable transfectants. 
HEK cells were transiently transfected with either pIREShyg vector alone (mock), 
Wild-type APP (Wt- APP) or the five histidine to alanine constructs (see Materials 






Figure 3.1. A schematic diagram of APP695 showing the location of the residues mutated in the 
current study.. GFD; Growth factor-like domain, CuBD; E1 copper binding domain 
 
incubated in UltraMEM™ for 24 h and cell lysates and conditioned medium samples 
were prepared (see Materials and Methods). 
 Initially the cell lysates were immunoblotted with the anti-APP C-terminal 
antibody. The results (Fig. 3.2A.) clearly show that both Wt-APP and the E2 CuBD 
mutants were highly over-expressed relative to the endogenous protein in mock-
transfected cells. Furthermore, excluding the APP-E2 CuBD H436A mutant, there 
were no significant differences between the expression of any of the E2 CuBD 
mutants and the over-expressed wild-type protein. HEK cells overexpressing the 
H436A mutant expressed approximately 1.4-fold more APP relative to the Wt-APP 
over-expressing cells.   The blots were then stripped and re-probed with the anti-actin 
antibody in order to confirm equal protein loading which was shown to be consistent 
between samples (Fig. 3.2B.). 
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 In order to examine any effects of the E2 CuBD mutations on the proteolysis 
of APP, the conditioned medium samples were then immunoblotted with the anti-APP 
6E10 antibody in order to detect soluble APPα fragments (sAPPα). The results (Fig. 
3.3.) show that, whilst the generation of sAPPα was clearly enhanced in the Wt-APP 
overexpressing HEK cells and E2 CuBD mutants (relative to the mock control), there 
was significantly less sAPPα generated by the E2 CuBD mutant constructs compared 
to the Wt-APP over-expressing cells. The conditioned medium samples were also 
Figure 3.2. APP expression levels in transiently transfected HEK cell lysates. The indicated 
constructs were transiently transfected into HEK cells and lysates were prepared and 
immunoblotted as described in the Materials and Methods section. A. Full-length APP was detected 
using the anti-APP C-terminal antibody. Results from triplicate immunoblots were quantified and 
the results are expressed as a percentage of the Wt-APP over-expressing cells (means ± S.D.). B. 
Cell lysates were immunoblotted using the anti-β-actin antibody in order to confirm equal protein 




Figure 3.3.  sAPP levels in medium from transiently transfected HEK cells. The indicated constructs 
were transiently transfected into HEK cells and conditioned medium samples were prepared and 
immunoblotted for sAPPusing antibody 6E10 as described in the Materials and Methods section. 
Results from triplicate immunoblots were quantified and the results are expressed as a percentage of the 
sAPPgenerated by the Wt-APP over-expressing cells (means ± S.D.). *, significant at P≤0.05; **, 
significant at P≤0.005 
 
immunoblotted with the anti-sAPPβ 1A9 antibody in order to detect sAPPβ. However, 
at the levels of APP overexpression achieved by transient transfection, no sAPPβ 





 Thus, it is apparent from these results that the transient transfection of the 
constructs into HEK cells resulted in APP over-expression as would be expected and 
that, excluding H436A, the histidine to alanine mutations in the APP E2 CuBD made 
no difference to the levels of APP expression. However, these results indicate that 
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mutations in the APP E2 CuBD may slightly reduce the non-amyloidogenic 
processing of APP.  
 
3.2.  Stable expression and proteolysis of constructs in HEK cells 
 For future toxicity experiments it was infeasible to use transiently transfected 
cells. Therefore, having confirmed that the constructs expressed correctly by transient 
transfection, stable HEK cell transfectants were also generated. Successfully 
transfected cells were selected using hygromycin B as described in the Materials and 
Methods section. In order to monitor APP expression and proteolysis, confluent cells 
were then incubated for 24h in UltraMEM® and lysate and conditioned medium 
samples were subsequently prepared (see Materials and Methods). 
 The lysates were initially immunoblotted using the anti-APP C-terminal 
antibody in order to detect the APP holoprotein. The results (Fig 3.4A) show that 
levels of APP were dramatically higher in lysates prepared from cells transfected with 
Wt-APP and the APP E2 CuBD mutants compared to the mock-transfected cells. 
Furthermore, there were no significant differences in APP holoprotein expression 
levels between cells over-expressing Wt-APP and any of the E2 CuBD mutants. 
Following probing for APP, the blots were stripped and subsequently re-probed for 
actin which showed equal loading of proteins across the samples (Fig 3.4B). 
 Previous studies have demonstrated that low concentrations of copper increase 
sAPPα secretion [98]. In order to determine if the binding of copper to the E2 CuBD 
of APP might be responsible for these previous observations, conditioned medium 
samples from the HEK stable transfectants in the current study were also 




Figure  3.4. APP expression levels in stably transfected HEK cell lysates. The indicated constructs were 
stably transfected into HEK cells and lysates were prepared and immunoblotted as described in the 
Materials and Methods section. A. Full-length APP was detected using the anti-APP C-terminal antibody. 
Results from triplicate immunoblots were quantified and the results are expressed as a percentage of the 
Wt-APP over-expressing cells (means ± S.D.). B. Cell lysates were immunoblotted using the anti-β-actin 




Figure 3.5.  sAPP and sAPPβ  levels in medium from stably transfected HEK cells. The indicated constructs were 
stably transfected into HEK cells and conditioned medium samples were prepared and immunoblotted for (A) 
sAPPusing antibody 6E10 and (B) sAPP using anti-sAPP antibody 1A9 (see Materials and Methods). Results from 
triplicate immunoblots were quantified and the results are expressed as a percentage of the sAPPor sAPPgenerated by 




The results (Fig. 3.5A) clearly showed that, whilst the amount of sAPPα generated 
was much higher in APP-transfected cells than in the mock controls, there were no 
significant differences between the amount of the fragment produced by Wt-APP 
over-expressing cells and those transfected with any of the E2 CuBD mutant 
constructs. Therefore, copper binding to the E2 domain did not impact on the non-
amyloidogenic processing of APP in this instance. 
 The same conditioned medium samples were probed separately for the 
amyloidogenic pathway proteolytic fragment sAPPβ, using antibody 1A9 which 
recognises a neoepitope on sAPPβ generated by β-secretase cleavage. The results (Fig. 
3.5B) again showed that the levels of this fragment were higher in all of the APP over-
expressing cell lines compared to the mock control. Only the APP-E2 CuBD H432A 
construct exhibited elevated sAPPβ generation relative to the Wt-APP-transfected 
control (1.38-fold increase). 
 
3.3.  Stable expression and proteolysis of constructs in SH-SY5Y 
cells 
 The neuroblastoma cell line SH-SY5Y is an extensively used model of AD as 
it exhibits neuronal-like properties [121]. Therefore, in order to determine the effects 
of the E2 CuBD mutants in a cell model of relevance to AD and to eliminate any cell-
type specific differences, the APP-E2 CuBD mutant constructs were also stably 
expressed in SH-SY5Y cells. Once stable transfectants had been selected using 
hygromycin, confluent cells were incubated for 24 h in UltraMEM®, and lysates and 
conditioned medium samples were prepared (see Materials and Methods). 
 The lysate samples were initially immunoblotted with the anti-APP C-terminal 
antibody in order to quantify the expression of the various constructs. As observed 
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previously in HEK cells, the Wt-APP and E2 CuBD domain over-expressing SH-
SY5Y cells exhibited dramatically higher APP expression compared to the mock cells 
(Fig. 3.6A). Of all the E2 CuBD mutants, only APP-E2 CuBD H436A and APP-E2 
CuBD AAAA were expressed at levels different to that of the over-expressed wild-
type protein (38% and 42% lower, respectively). Immunoblot analysis of actin levels 





Figure  3.6. APP expression levels in stably transfected SH-SY5Y cell lysates. The indicated constructs 
were stably transfected into SH-SY5Y cells and lysates were prepared and immunoblotted as described in 
the Materials and Methods section. A. Full-length APP was detected using the anti-APP C-terminal 
antibody. Results from triplicate immunoblots were quantified and the results are expressed as a percentage 
of the Wt-APP over-expressing cells (means ± S.D.). B. Cell lysates were immunoblotted using the anti--






Figure 3.7.  sAPP and sAPP  levels in medium from stably transfected SH-SY5Y cells. The indicated 
constructs were stably transfected into SH-SY5Y cells and conditioned medium samples were prepared and 
immunoblotted for (A) sAPPusing antibody 6E10 and (B) sAPP using anti-sAPP antibody 1A9 (see 
Materials and Methods). Results from triplicate immunoblots were quantified and the results are expressed as a 





 The conditioned medium samples from the SH-SY5Y stable transfectants were 
then immunoblotted with antibody 6E10 in order to quantify sAPPα. The results (Fig. 
3.7A) revealed no significant changes in sAPPα generation associated with the 
introduction of mutations in the E2 CuBD. Immunoblotting of the same samples with 
antibody 1A9 (Fig. 3.7B) also showed no change in the generation of sAPPβ in the E2 
CuBD mutant expressing cells. Thus, it is apparent that, despite some variation in the 
expression levels of the APP constructs, there were no significantly different changes 
observed in either the amyloidogenic or non-amyloidogenic processing of the 
proteins. 
 
3.4.  Subcellular localisation of constructs in stable SH-SY5Y 
transfectants 
 In order to determine whether altered copper binding to the APP E2 CuBD 
affected the subcellular localisation of APP, SH-SY5Y cells stably transfected with 
either Wt-APP or the APP-E2 CuBD constructs were subjected to 
immunofluorescence as described in Materials and Methods. The antibody employed, 
ab15272 (Abcam, Cambridge, UK), recognises an epitope within amino acids 44-62 
of APP and, therefore, detects the N-terminal region of all three major APP isoforms. 


































































































Figure 3.8. Immunofluorescence detection of APP expression in SH-SY5Y stable transfectants. Cells were cultured on cover-
slips and fixed and stained with ab15272 as described in the Materials and Methods section. A, C, E, G, I, K, M, detection of APP. 
B, D, F, H, J, N, co-detection of DAPI stained nuclei and APP. (n=1) 
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The results (Fig. 3.8) show enhanced fluorescence in the APP over-expressing cell 
lines compared to the mock-transfected cells. Clearly endogenous APP was also 
detected in the mock cells. In all of the cell lines, APP expression was detected mainly 
as peri-nuclear fluorescence consistent with a predominantly ER/Golgi localisation. 
The pattern of fluorescence did not differ substantially between the Wt-APP over-
expressing cells and any of the APP E2 CuBD mutant cells indicating that copper 
binding to the E2 domain did not alter the subcellular localisation of APP. 
 
3.5.  Role of the APP E2 CuBD in cytotoxicity 
 Previous studies have indicated that the APP E1 CuBD might be involved in 
the regulation of copper-induced neurotoxicity [102]. In the current study, it was 
hypothesized that the E2 CuBD domain may act in a similar manner.  
 
3.5.1. Free copper-mediated neurotoxicity 
 Although the concentration of copper in the circulation is much lower, copper 
concentrations of up to 400 μM have been observed in amyloid plaques [104]. 
Furthermore, previous studies have employed free copper concentrations of up to 250 
μM when studying the effect of metal toxicity on neuronal cell lines [35]. As a result, 
in this section of the current study, copper concentrations of up to 200 μM were 
considered appropriate. HEK and SH-SY5Y cells stably transfected with either Wt-
APP or the various APP E2 CuBD mutants were grown to confluence and then 
incubated for 48 h in the absence or presence of CuSO4.5H2O (0-200 μM). Cell 
viability was then determined using the CellTiter 96® AQueous One Cell 
proliferation Assay as described in the Materials and Methods section. In the case of 
HEK cells, the results (Fig. 3.9) show that, following treatment with the lower 50 μM 
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copper concentration, the viability of the mock transfectants actually increased 
significantly. Although only small, this increase in viability may have been due to a 
minor growth stimulating effect of copper at lower concentrations compared to 200 
μM metal at which concentration the viability of the mock transfectants was reduced 
(82% of the untreated mock-transfectants). In terms of the APP transfected cells, 
metal-mediated toxicity was only observed at the highest copper concentration (200 
μM). At this concentration, viability in Wt-APP transfected cells was significantly 
lower than mock transfectants (81% of mock transfectants in 200μM copper) which 
suggests that APP potentiates copper induced neurotoxicity. Of the APP-E2 CuBD 
mutants, H382A significantly reversed the reduction of cell viability observed in Wt-
APP transfectants returning viability to the levels observed in mock transfectants. This 
indicates that, as hypothesised, the APP E2 CuBD may regulate copper induced 
toxicity.  
In terms of the SH-SY5Y stable transfectants, the results (Fig. 3.10) revealed 
that none of the copper concentrations employed actually resulted in significant 
cytotoxicity. It could, therefore, not be determined whether or not APP had any effect 













Figure 3.9.  The effect of free copper on the viability of HEK cell stable transfectants. The cells 
were grown to confluence and then treated for 48 h with the indicated concentrations of 
CuSO4.5H2O. The cell viability was then determined using the CellTiter 96® AQueous One Cell 
proliferation Assay as described in the Materials and Methods section. The results for each cell line 
are expressed relative to the viability in the absence of copper of that particular cell line. The results 













Figure 3.10.  The effect of free copper on the viability of SH-SY5Y cell stable transfectants. 
The cells were grown to confluence and then treated for 48 h with the indicated concentrations of 
CuSO4.5H2O. The cell viability was then determined using the CellTiter 96® AQueous One Cell 
proliferation Assay as described in the Materials and Methods section. The results for each cell line 
are expressed relative to the viability in the absence of copper of that particular cell line. The results 




3.5.2. Copper-glycine-mediated neurotoxicity 
 In the preceding section, free copper was employed in order to examine the 
effect of APP on metal-mediated cytotoxicity. However, the majority of copper in the 
brain and elsewhere in the body exists in a protein bound form [85]. In order to 
improve the physiological relevance of the current study, the effect of glycine-
complexed copper on the viability of the various HEK and SH-SY5Y APP stable 
transfectants was also examined.  
 Cells were grown to confluence and then treated with the indicated 
concentrations of glycine-copper complexes for 24 h (the concentration refers to the 
final metal concentration in the culture medium). Cell viability was once more 
determined using the CellTiter 96® AQueous One Cell proliferation Assay as 
described in the Materials and Methods section.  
 Before examining the effect of any of the APP stable transfections on toxicity, 
metal dose-response curves were established in mock-transfected cells. In relation to 
the HEK cells, the dose response results (Fig. 3.11) show that cells were resistant to 
the lowest metal concentration of 150 μM but that toxicity increased in a dose-
dependent manner right up to 700 μM copper. Having established that the minimum 
copper concentration required to kill HEK cells was 250 μM, this 'threshold' toxicity 
concentration, along with one higher metal concentration (600 μM) were used to treat 
the various APP stably-transfected HEK cell lines. As described above, confluent cells 
were incubated for 24 h in the presence of the indicated copper-glycine complex 
concentrations and cell viability was subsequently determined as described in the 






















Figure 3.11.  The effect of glycine-complexed copper on the viability of mock-transfected HEK 
cells. The cells were grown to confluence and then treated for 24 h with the indicated concentrations 
of metal in the form of glycine-complexed copper chloride. The cell viability was then determined 
using the CellTiter 96® AQueous One Cell proliferation Assay as described in the Materials and 
Methods section. Panels A and B represent data from separate experiments using different metal 















Figure 3.12.  The effect of glycine-complexed copper on the viability of HEK cell stable 
transfectants. The cells were grown to confluence and then treated for 24 h with the indicated 
concentrations of metal in the form of glycine-complexed copper chloride. The cell viability was 
then determined using the CellTiter 96® AQueous One Cell proliferation Assay as described in the 
Materials and Methods section. The results for each cell line are expressed relative to the viability in 
the absence of copper of that particular cell line. The results shown are means ± S.D (n=3).  *, 




 The results (Fig. 3.12) demonstrated a clear reduction in the viability of mock-
transfected HEK cells at both 250 μM and 600 μM copper concentrations (68% and 
40% respectively). Cells over-expressing Wt-APP exhibited a significant decrease in 
viability at 600 μM copper compared to the mock-transfected HEK cells. Most of the 
APP-E2 CuBD mutant-transfected cells exhibited viability unchanged from that of the 
Wt-APP transfected cells at both of the metal concentrations employed, indicating that 
the E2 CuBD domain was not responsible for the increased sensitivity of APP-
transfected cells to copper toxicity. The one exception in this respect was that of the 
APP-E2 CuBD H436A mutant which exhibited viability indistinguishable from that of 
the mock-transfected cells at both 250 μM and 600 μM copper concentrations. Thus, it 
would appear that histidine 436 may well be involved in mediating the toxic effects of 
glycine-copper complexes although it is not clear why the quadruple substitution 
mutant, APP-E2 CuBD AAAA did not exhibit a similar effect. 
 Having determined the effects of the various APP stable transfections on 
glycine-copper mediated toxicity to HEK cells, similar results were conducted in SH-
SY5Y cells. Initially, copper toxicity does response was examined in mock-
transfected cells. The results (Fig. 3.13) show that SH-SY5Y cells were considerably 
more resilient than HEK cells to glycine-copper-induced toxicity with only metal 
concentrations greater than 500 μM generating appreciable cell death.  
 On the basis that APP might actually enhance toxicity (as seen for HEK cells), 
one sub-toxic metal concentration along with a known toxic concentration (250 μM 
and 600 μM) were then utilised in order to examine the effects of APP on metal-
induced toxicity in SH-SY5Y cells. As previously, the various mock- and APP-
transfected SH-SY5Y cell lines were incubated with the indicated metal 











Figure 3.13.  The effect of glycine-complexed copper on the viability of mock-transfected SH-
SY5Y cells. The cells were grown to confluence and then treated for 24 h with the indicated 
concentrations of metal in the form of glycine-complexed copper chloride. The cell viability was 
then determined using the CellTiter 96® AQueous One Cell proliferation Assay as described in the 
Materials and Methods section. Panels A and B represent data from separate experiments using 














Figure 3.14.  The effect of glycine-complexed copper on the viability of SH-SY5Y cell stable 
transfectants. The cells were grown to confluence and then treated for 24 h with the indicated 
concentrations of metal in the form of glycine-complexed copper chloride. The cell viability was 
then determined using the CellTiter 96® AQueous One Cell proliferation Assay as described in the 
Materials and Methods section. The results for each cell line are expressed relative to the viability in 
the absence of copper of that particular cell line. The results shown are means ± S.D. (n=3). *, 




 The results (Fig. 3.14) demonstrated, as might have been expected from the 
previous dose-response experiment, a lack of glycine-copper-induced cytotoxicity at 
the lower, 250 μM, metal concentration.  In contrast, at the higher, 600 μM, 
concentration, all of the cell lines exhibited major decreases in viability. As observed 
previously, the viability of the mock-transfected cells at this higher metal 
concentration was greater than that of the Wt-APP-transfected cells suggesting that 
the protein increases the sensitivity of the cells to metal toxicity. Mutating the APP-E2 
CuBD did not prevent the increase in toxicity observed in the Wt-APP-transfected 
cells. This further demonstrates that this domain is not essential for the toxic effect of 
Wt-APP in increased copper concentrations.  
 
3.6.  Summary  
 Initially, all of the APP constructs were transiently expressed in HEK cells 
where the holoprotein expression was equal between constructs with the exception of 
the APP-E2 CuBD H436A protein which was expressed significantly more highly 
relative to the over-expressed wild-type protein. The levels of sAPPα generated from 
all of the APP-E2 CuBD mutant proteins were significantly lower than that produced 
from the over-expressed wild-type protein. No sAPPβ could be detected in 
conditioned medium from the transient transfectants. 
 In terms of the stable transfectants, the expression of the APP holoprotein was 
identical in all of the HEK cell lines as were the levels of sAPPα generated. The only 
significant change was a small increase in the amount of sAPPβ generated from the 
APP-E2 CuBD H432A protein. In the SH-SY5Y stable transfectants, the expression 
of APP-E2 CuBD H436A was slightly lower than that of the over-expressed wild-type 
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protein but the generation of sAPPα and sAPPβ from the mutant constructs was 
identical to that from the over-expressed wild-type protein. 
 Immunofluorescence detection of the constructs in stably transfected SH-
SY5Y cells showed a predominant peri-nuclear staining which did not appear 
different between the over-expressed wild-type protein and any of the mutant 
constructs. 
 Finally, the copper toxicity studies using free copper (copper sulphate) 
revealed that SH-SY5Y cells were more resilient to this metal than the HEK cells, 
showing no cell death at the concentrations used. The viability of the mock-
transfected HEK cells was significantly decreased at 200 μM copper; an effect which 
was enhanced in the presence of over-expressed Wt-APP. The toxic effect of Wt-APP 
was reversed by the APP-E2 CuBD H382A mutation. 
 When glycine-complexed copper was used instead of free copper, Wt-APP 
again increased the sensitivity of HEK cells to metal toxicity. In these latter 
experiments, the toxic effect of APP was reversed by the APP-E2 CuBD H436A 
mutation. In contrast, whilst Wt-APP also enhanced glycine-copper toxicity in the SH-
























4.1.  Discussion 
The APP-E2 CuBD is a novel copper binding site, for which the function is 
currently unknown. The main aim of this project was, therefore, to analyse the role of 
the APP-E2 CuBD in APP expression, proteolysis, copper induced neurotoxicity and 
localisation. The APP-E2 CuBD consists of co-ordinating histidine residues at 
positions 313, 382, 432 and 436 located in three α-helices and which binds copper 
with a strong affinity (≤13nM). Determining the role of this binding site will help to 
elucidate the relationship between copper dyshomeostasis and AD, and may provide 
novel therapeutic targets. 
Previous studies have shown that increased copper alters APP expression and 
proteolysis [98]. The amyloid cascade hypothesis remains a key theory in the 
pathogenesis of AD with the majority of therapeutic interventions geared towards 
reducing Aβ levels in the brain [122]. Therefore, the initial aim of this project was to 
determine if the APP-E2 CuBD influences the expression and proteolysis of APP. To 
do this, APP695 mutants containing single histidine to alanine mutations in the E2 
CuBD copper binding residues (313, 382, 43, 436) and a quadruple mutation were 
overexpressed in HEK and SH-SY5Y cells by two methods, transient and stable 
overexpression. The mutant constructs were overexpressed alongside ‘mock’ 
(pIREShyg empty vector) and Wt-APP695 transfections as negative and positive 
controls.  
 
4.1.1. APP expression 
Transient and stable overexpression of APP-E2 CuBD mutants resulted in no 
consistent difference in APP expression levels relative to Wt-APP. Any variances in 
APP levels observed were cell line specific, indicating that APP expression is not 
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influenced by the APP-E2 CuBD. Previous studies have shown that copper overload 
significantly up regulates APP mRNA levels in cells, which suggests that copper acts 
as a transcriptional regulator of the APP gene [95]. A putative copper responsive 
element in the APP promoter region has been identified which reduced APP levels by 
80% when deleted [96]. Thus, it is more likely that copper influences APP expression 
through a copper response element in the promoter region, rather than binding to the 
E2-CuBD.  
The current study quantified APP holoprotein expression in cell lysates, 
however APP mRNA was not analysed. Bellingham et al. [96] showed an 80% 
decrease in mRNA with a decrease of APP protein in copper deficient cells, which 
was associated with a 75% reduction in APP promoter activity. However Cater et al. 
[94] found that APP protein expression remained constant despite a decrease in 
mRNA, indicating that copper deficiency decreases transcription but increases 
translation. Future work may include quantifying the APP mRNA in cells transfected 
with APP-E2 CuBD mutants using real-time RT-PCR to determine if this domain 
mediates copper induced differences in APP translation. 
 
4.1.2. APP proteolysis 
Once APP expression levels had been determined, the next aim was to 
determine if the APP-E2 CuBD modulated APP proteolysis. Previously, copper 
concentrations between 20 and 50 μM have been shown to increase non-
amyloidogenic APP processing by ≈200% relative to basal levels; the increase was 
only 50% of the basal level when cells were co-incubated with the metal and a copper 
chelator [98]. In contrast, copper deficiency stimulates amyloidogenic processing and 
the co-localisation of copper and APP to lipid rafts [100]. It is currently not known 
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how copper increases non-amyloidogenic processing, however it is hypothesised that 
metal binding to APP stimulates a conformational change that permits differential 
access to enzymes [98] or trafficking proteins such as Fe65 or Sor/La [119]. In the 
current study, immunoblotting of conditioned media from the stable HEK and SH-
SY5Y transfectants revealed that Wt-APP overexpression dramatically increased 
sAPPα and sAPPβ levels relative to the cognate mock-transfected controls. However, 
there was no consistent alteration in sAPPα or sAPPβ shedding in cells stably 
expressing APP-E2 CuBD mutants compared to Wt-APP expressing cells. This result 
was important as it demonstrates that the APP-E2 CuBD does not seem to regulate 
APP proteolysis. Conversely, HEK cells transiently overexpressing the APP-E2 
CuBD mutants exhibited significantly decreased sAPPα production relative to Wt-
APP-transfected cells, although there was no reciprocal increase in lysate APP 
holoprotein levels. Initially this result appears contradictory. However, an increase in 
APP holoprotein levels would not be observed if the protein was immediately 
processed by α- and β- secretase. Therefore, these results suggest that Wt-APP 
overexpressing cells exhibited increased APP holoprotein levels with subsequently 
increased sAPPα levels with no resultant net detection of steady state holoprotein 
levels in cell lysates. A limit of transient transfection is that there is no antibiotic 
selection to ensure successful uptake of the constructs in all the cells analysed. It is, 
therefore, possible that the transient transfection of Wt-APP695 was more successful 
than the APP-E2 CuBD mutants, leading to increased proteolysis and sAPPα 
generation within the short time frame involved.  
Previous studies have implicated the APP-E1 CuBD in APP proteolysis.  
Spoerri et al. [117] mutated E1-CuBD binding residues to asparagine, which 
significantly decreased APP processing. In addition Borchardt et al. [98] demonstrated 
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that low levels of copper increase non-amyloidogenic processing which they further 
showed is abolished when the CuBD is mutated [123]. Taken with our results, these 
data support the E1 CuBD, rather than the E2 CuBD as a regulator of APP proteolysis. 
Recently our laboratory generated HEK and SH-SY5Y cells overexpressing APP E1-
CuBD histidine to alanine mutations in the copper binding residues [124]. This 
mutation was considered conservative due to the helix-promoting properties of 
alanine. The E1-CuBD mutants failed to affect both the maturation and proteolysis of 
APP relative to Wt-APP, which suggests that, in conflict to Spoerri et al [117] the 
APP-E1 CuBD copper binding site is not implicated in APP processing. The disrupted 
APP processing observed in the E1 CuBD copper binding mutants generated by 
Spoerri et al [117]  is likely a result of mutating histidine to asparagine, which due to 
its’ helix breaking properties would induce significant conformational change in the 
protein. Therefore it currently appears that neither the E1 nor E2 copper binding site 
influence APP processing. 
4.1.3. APP localisation 
Nascent APP is trafficked along the secretory pathway to the cell surface, 
where it is quickly re-internalised to lysosomes where most is degraded [125]. Copper 
(150 μM) has been shown to stimulate APP redistribution to the cell-surface, however 
the mechanism by which copper influences APP sub-localisation is unknown. As 
discussed previously, Dahms et al. [119] proposed that the copper induced 
conformational change observed in the APP-E2 CuBD may alter access for trafficking 
proteins such as Sor/La, subsequently regulating APP localisation. Therefore, one aim 
of the current project was to determine if mutating the APP-E2 CuBD altered APP 
sub-cellular localisation.  
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SH-SY5Y cells overexpressing the APP-E2 CuBD mutants or Wt-APP were 
subject to immunofluorescence confocal microscopy to detect APP subcellular 
localisation. This revealed a pronounced perinuclear localisation of APP. In the 
copper-free conditions employed in this study, mutating the copper binding residues 
of the APP-E2 CuBD did not alter APP subcellular localisation relative to Wt-APP 
overexpressing cells. A limitation of IF confocal microscopy is that, as a result of the 
whole cell being stained, there is increased risk of cross-reactivity compared to 
techniques that analyse specific cell fractions and this must be considered when 
interpreting results. Using a different primary antibody to stain for APP may reduce 
this problem.  
 Co-stains for organelle markers were not used for the comparison of APP 
localisation in this study. However, previous studies have utilised Golgi and ER 
markers to confirm the subcellular localisation of APP to a specific part of the 
constitutive secretory pathway [117]. Repeating this experiment with co-stains for 
organelle markers would further support the data obtained.  
 
4.1.4. Copper-mediated cytotoxicity 
As discussed in the introduction, high levels of copper are neurotoxic to cells. 
However, studies exploring the role of APP in response to copper are conflicting with 
evidence supporting both a neuroprotective function [102] and a role as a potentiator 
of copper induced cytotoxicity [35]. The final aim of the current project was, 
therefore, to determine if mutating the APP-E2 CuBD altered cytotoxicity in response 
to copper. HEK and SH-SY5Y cells stably transfected with the APP-E2 CuBD 
mutants or Wt-APP were incubated in a range of concentrations of free or glycine-
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complexed copper. Following this a cell proliferation test was performed to quantify 
viability. 
Initially, both HEK and SH-SY5Y cells were incubated in ‘free’ copper 
sulphate and viability was determined. In mock-transfected HEK cells, 50 μM copper 
sulphate significantly enhanced cell viability to 117% relative to the copper-free 
control (Fig. 3.12). The average copper level in the neuropil of healthy individuals has 
been determined at ≈ 79μM [104] suggesting that such a metal concentration is 
suitable for normal healthy cell function.  Thus, in the current study, the increased cell 
viability observed at 50 μM copper may be a consequence of the metal's involvement 
in essential cell enzyme function such as cytochrome c oxidase, lysyl oxidase, 
ceruloplasmin, superoxide dismutase and catechol oxidase activities [83]. However, 
the result appears cell line specific and was not replicated in SH-SY5Y cells.  
Copper can accumulate in synaptic clefts to concentrations of  ≈100 μM [126], 
and in Aβ senile plaques to concentrations of ≈400 μM [104]. The concentrations used 
in the current study (50-600 μM) are within the same order of magnitude as these 
values and can, therefore, be considered of biological relevance. HEK cells 
overexpressing Wt-APP exhibited significantly reduced cell viability (≈15%) relative 
to the mock-transfected controls in the presence of 200 μM copper sulphate and 600 
μM glycine-complexed metal.  In addition, SH-SY5Y cells overexpressing Wt-APP 
exhibited reduced cell viability (≈13%) relative to mock-transfected controls in 600 
μM glycine-complexed copper. These data suggest that APP potentiates cytotoxicity 
in the presence of higher copper concentrations. These data are in agreement with 
White et al. [35] who determined a ≈20% reduction in viability in wild-type APP 
neurons compared with APP knock-out neurons in the presence of 100 μM copper.  
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HEK cells overexpressing the APP-E2 CuBD mutants (with the exception of 
the H436A construct) did not demonstrate altered viability in the presence of copper 
relative to Wt-APP over-expressing cells. HEK cells transfected with the H436A 
construct exhibited significantly increased cell viability at both 250 and 600 μM 
glycine-complexed copper relative to wild-type overexpressing cells. However, this 
observation was not duplicated in SH-SY5Y cells suggesting that it was cell line 
specific. Taken together, it appears from these data that the APP-E2 CuBD does not 
mediate the increased cytotoxicity observed in Wt-APP overexpressing cells.  
APP may facilitate neurotoxicity through the increase of Aβ deposition.  Aβ 
fibrils have previously been detected in cell medium after only a 24 h incubation 
[106]; the same time frame used in the current cytotoxicity experiments. It is, 
therefore, conceivable that the increased copper-mediated cytotoxicity observed in 
APP over-expressing cells in the current study was due to the enhanced accumulation 
of Aβ-peptides in conditioned medium. Indeed copper incubation increases Aβ 
oligomer/fibril ratio [106] and supplementing drinking water with copper in 
cholesterol fed rabbits induces amyloid plaques and learning deficits [127]. However 
other studies have shown that copper decreases the Aβ-42/Aβ-40  ratio and reduces 
Aβ generation [98], and results are often limited to specific species or cell lines [94].  
Collectively, the current data indicates that the APP E2 CuBD is not involved 
in the ability of the protein to enhance metal-mediated cytotoxicity. Indeed this 
conclusion is supported by the work of Cerpa et al. [102] who concluded that the APP 
E1 CuBD was sufficient for the protective effect of APP-overexpression in increased 
copper concentrations -. Specifically, the authors showed that the reduced toxicity was 
due to the ability of Cys 144 within the APP molecule to reduce Cu (II) to Cu (I)  
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Interestingly, in the current study, SH-SY5Y cells seemed generally more 
resilient to copper-mediated cytotoxicity than HEK cells suggesting that the two cell 
types may have varying abilities to protect themselves against the metal. In fact, 
enhanced glutathione levels indicate that human neuron-related cells such as SH-
SY5Y exhibit decreased anti-oxidant defence capability compared with cells derived 
from other tissues [128]. 
 
4.2.  Conclusions and future directions 
In summary, these data clearly show that that the APP-E2 CuBD is not 
involved in APP maturation, processing or localisation in the absence of exogenous 
copper.  Viability assays showed that APP overexpression is cytotoxic in increased 
copper concentrations; however the APP-E2 CuBD does not mediate this toxicity. 
Some of the cell-line specific results obtained from this project highlight the influence 
of cell line on data acquisition. Indeed, Cater et al. [94] found that the differences in 
APP proteolysis observed in copper deficient fibroblasts were not replicated in SH-
SY5Y neuronal cells. To improve reliability of these data, experiments could be 
replicated in further cell lines.  
One additional limitation of the current study was that the effects of exogenous 
copper on the expression and proteolysis of the various over-expressed constructs 
were not investigated. These experiments would be difficult to perform in the current 
cell models as both HEK and SH-SY5Y cells express quite high endogenous levels of 
APP which might confound the effects of copper on any transfected forms of APP. 
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